← All trials
NCT06272630
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 6, 2023
- Primary completion
- May 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Feb 22, 2024
- Last posted
- Apr 26, 2024
- Enrollment
- 258
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daewoong Pharmaceutical Co. LTD.Lead sponsor
- Soonchunhyang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.